Enter Note Done
Go to previous page in this tab
Session
  • Presentation | Developing Topics Session - Developing Topics in Phase 1 and Phase 2 Clinical Trials
  • Developing Topics Session
  • From Bench To Bedside: Safety And Biomarker Effects Of Anti-PD-L1 IBC-Ab002 Immunotherapy In Early Alzheimer’S Patients
  • ICC Auditorium
    Set Timezone

Tommaso Croese1, Catherine Mummery2, Noa Bregman, MD3, Dalia Bracha1, Kuti Baruch1, Alex Kertser1, Sharona Raveh1, Michal Schwartz4.
1ImmunoBrain Checkpoint, Inc., Palm Beach Gardens, FL, USA, 2University College London, United Kingdom, 3Cognitive Neurology, Tel Aviv Medical Center, Tel Aviv, Israel, 4Brain Sciences, Weizmann Institute of Science, Rehovot, Israel.
Types
Main Session